Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(50.0%)

Phase 1

3(37.5%)

Phase 2

1(12.5%)

8Total

N/A(4)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02593123Phase 2Completed

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Role: collaborator

NCT03996642Not ApplicableCompleted

Feasibility of Delivering an Avatar Life-review Intervention to Support Patients With Active Cancer

Role: collaborator

NCT01075113Phase 1Completed

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Role: collaborator

NCT02875002Phase 1Withdrawn

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Role: collaborator

NCT02564549Not ApplicableTerminated

MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca

Role: collaborator

NCT02584296Not ApplicableCompleted

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

Role: collaborator

NCT02410564Not ApplicableTerminated

CBT-I Intervention for Insomnia in Newly Diagnosed Cancer Patients

Role: collaborator

NCT01276717Phase 1Completed

Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Role: collaborator

All 8 trials loaded